Prevention of opportunist infections among adult and adolescent patients infected with the HIV in the era of highly active anti-retroviral therapy;Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretrovírico de gran actividad: Recomendaciones del grupo de estudio del sida (gesida)/plan nacional sobre el sida

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 18, Issue 9, 2000, Pages 457-468

  Berenguer, J ^a   Laguna, F ^a   Lopez Aldeguer J ^a   Moreno, S ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ATOVAQUONE; AZITHROMYCIN; CIDOFOVIR; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; FAMCICLOVIR; FANSIDAR; FLUCONAZOLE; FOLINIC ACID; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; HEPATITIS VACCINE; HERPES ZOSTER IMMUNOGLOBULIN; ISONIAZID; ITRACONAZOLE; PENTAMIDINE; PNEUMOCOCCUS VACCINE; PYRAZINAMIDE; PYRIMETHAMINE; RIFABUTIN; RIFAMPICIN; SULFADIAZINE; UNINDEXED DRUG; VALACICLOVIR;

ADOLESCENT; ADULT; CYTOMEGALIC INCLUSION BODY DISEASE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; MYCOBACTERIOSIS; MYCOSIS; OPPORTUNISTIC INFECTION; PARASITOSIS; REVIEW; VIRUS INHIBITION;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDIASIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PARASITIC DISEASES; TUBERCULOSIS, PULMONARY;

EID: 0034491142     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS
2. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study
5. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
6. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
7. Cytomegalovirus retinitis: New developments in prophylaxis and therapy
8. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy
9. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy
10. Impacto del tratamiento de combinacion con inhibidores de proteasa en la retinitis por CitomegaIovirus en pacientes con SIDA
11. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis
12. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy
13. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS
14. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals
15. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
16. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS
17. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: Recommendations of an international panel
18. Treat of cytomegalovirus retinitis with a sustained-release ganciclovir implant
19. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant
20. Fomivirsen
21. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
22. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts
23. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
24. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
25. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to HAART
26. GESIDA EM 07/98. A 2-year multicenter study of CMV retinitis in AIDS patients receiving protease inhibitor therapy
27. 1998 guidelines for treatment of sexually transmitted diseases
28. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Fractices (ACIP)
29. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP)
30. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
31. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
32. Treatment of AiDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy
33. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection
34. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphism
35. Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: Revised recommendations
36. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus
37. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis
38. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
39. Reversion of cutaneous anergy and the tuberculin skin test after initiation of highly active antiretroviral therapy (HAART) in HIV-infected patients with CD4 counts < 50/uL
40. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy
41. Risk for developing tuberculosis among anergic patients infected with HIV
42. A prospective study of the risk of tuberculosis among HIV-infected patients
43. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
44. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival
45. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: Results of a randomized controlled trial
46. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia
47. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: An international randomized trial
48. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection
49. Targeted tuberculin testing and treatment of latent tuberculosis infection
50. The safety of Bacille Calmette-Guerin vaccination in HIV infection and AIDS
51. Treatment of tuberculosis in HIV-infected patients. Safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin
52. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers
53. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors
54. Ritonavir enables combined therapy with rifampin and saquinavir
55. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both
56. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome
57. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy
58. Eradication of disseminated Mycobacterium avium complex in four patients after twelve months antimycobacterial therapy and response to highly active antiretroviral therapy
59. Discontinuing or withholding primary prophylaxis against M. avium in patients on successful antiretroviral combination therapy: The Swiss HIV cohort experience
60. Withdrawal of Mycobacterium avium complex suppressive therapy in HIV-1-infected patients on highly active antiretroviral therapy
61. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis
62. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
63. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS
64. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome
65. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis
66. Discontinuation of antifungal therapy for cryptococcosis after immunological response to antiretroviral therapy
67. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus
68. Linfocitos CD4+ e infecciones oportunistas y neoplasias en pacientes con infección per el virus de la inmunodeficiencia humana
69. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1
70. Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm3
71. Difference in the incidence rates of opportunistic infections before and after the availability of protease inhibitors
72. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
73. Pneumocystis carinii infection: Evidence for high prevalence in normal and immunosuppressed children
74. Genetic variation in Pneumocystis carinii isolates from different geographic regions: Implications for transmission
75. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: Reassessment of indications for chemoprophylaxis
76. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients
77. Daily versus thrice weekly trimethoprim-sulfamethoxazole (TMP/SMX) in the prevention of Pneumocystis carinii pneumonia (PCP)
78. Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients
79. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): Use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ
80. Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients
81. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia
82. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection
83. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia
84. Primary prophylaxis for Pneumocystis carinii pneumonia: A randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine
85. Fansidar for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in AIDS patients with poor compliance
86. Pirimetamina y sulfadoxina como tratamiento preventivo para la neumonía por Pneumocystis carinii y la encefalitis por Toxoplasma
87. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome
88. Discontinuation of PCP prophylaxis (PRO) is safe in HIV-infected patients (PTS) with immunological recovery with HAART. Preliminary results of an open, randomized and multicentric clinical trial (GESIDA04/98)
89. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
90. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy
91. Is it safe to discontinue secondary prophylaxis for PCP in HIV-infected patients treated with HAART: Results from eight prospective european cohorts
92. Toxoplasmic encephalitis in AIDS
93. Toxoplasmosis: Parasite life cycle, pathology and immunology
94. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: A double-blind, randomized trial
95. Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients
96. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients
97. Trimethoprim-sulfamethoxazole versus dapsone plus pyrimethamine as primary prophylaxis of CNS toxoplasmosis and P. carinii pneumonia in HIV-infected patients
98. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis
99. Cerebral toxoplasmosis and prophylaxis for Pneumocystis carinii pneumonia
100. Central nervous system toxoplasmosis in AIDS patients: Efficacy of an intermittent maintenance therapy
101. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS
102. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients
103. Discontinuation of toxoplasmic encephalitis prophylaxis is safe in HIV-1 and T. gondii co-infected patients after immunological recovery with HAART: Preliminary results of the GESIDA 04/89-B study
104. Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy
105. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis
106. Leishmania and human immunodeficiency virus coinfection: The first 10 years
107. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients
108. Discontinuation of secondary anti-Lesihmania prophylazis in human immunodeficiency virus-infected patients who have responded to HAART
109. The species of Cryptosporidium (Apicomplexa: Cryptosporidiidae) infecting mammals
110. Cryptosporidiosis in patients infected with the human immunodeficiency virus
111. Intestinal and extraintestinal cryptosporidiosis in AIDS patients
112. Apparent chemoprophylaxis of cryptosporidiosis with clarithromycin and rifabutin
113. Enterocytozoon bieneusi (Microspora): Prevalence and pathogenicity in AIDS patients
114. Enteropatía crónica de etiología desconocida en pacientes con sida. Análisis de 40 casos
115. Enteritis pot Isospora belli en pacientes con SIDA. Descripción. de nueve casos
116. Incidencia de enteropatógenos en pacientes con infección per el virus de la inmunodeficiencia humana